ADHD Individual Drug Risk Studies To Be Considered By Drug Safety Committee

FDA to present analysis of sudden death and serious cardiovascular event rates with amphetamine and methylphenidate products at Feb. 9 meeting of Drug Safety & Risk Management Advisory Committee.